Case Western Reserve University
case.eduTotal trials
158
Active
38
Phase 3
3
Total enrollment
61,862
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Semaglutide Injectable Product | — | — | — | — | — | 1 | |
| local antibiotic application of topical minocycline | — | — | — | — | — | 1 |
Next readouts
- 2024-04-30
- 2027-06
Top conditions
- Bipolar Disorder11
- Hypertension10
- Dementia7
- Dental Caries6
- Multiple Sclerosis6
- Stroke6
- Depression5
- Caregiver Burden4
Frequently asked questions about Case Western Reserve University
- How many clinical trials does Case Western Reserve University have on ClinicalTrials.gov?
- Case Western Reserve University is listed as the lead sponsor on 158 clinical trials in ClinicalTrials.gov, 38 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Case Western Reserve University's trials are in Phase 3?
- 3 of Case Western Reserve University's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Case Western Reserve University focus on?
- Case Western Reserve University's most-studied conditions on ClinicalTrials.gov are Bipolar Disorder, Hypertension, Dementia, Dental Caries, Multiple Sclerosis.
- When are Case Western Reserve University's next clinical trial readouts?
- Case Western Reserve University has 2 upcoming primary-completion readouts tracked here; the soonest is “Effects of Semaglutide in HIV-Associated Lipohypertrophy”, expected around 2024-04-30.